SG11201401207XA - Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication - Google Patents

Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Info

Publication number
SG11201401207XA
SG11201401207XA SG11201401207XA SG11201401207XA SG11201401207XA SG 11201401207X A SG11201401207X A SG 11201401207XA SG 11201401207X A SG11201401207X A SG 11201401207XA SG 11201401207X A SG11201401207X A SG 11201401207XA SG 11201401207X A SG11201401207X A SG 11201401207XA
Authority
SG
Singapore
Prior art keywords
inhibitors
cancers
hepatocellular carcinoma
virus replication
hepatitis virus
Prior art date
Application number
SG11201401207XA
Other languages
English (en)
Inventor
Andrea Cuconati
Xiaodong Xu
Timothy M Block
Original Assignee
Inst Hepatitis & Virus Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Hepatitis & Virus Res filed Critical Inst Hepatitis & Virus Res
Publication of SG11201401207XA publication Critical patent/SG11201401207XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201401207XA 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication SG11201401207XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542907P 2011-10-04 2011-10-04
PCT/US2012/058674 WO2013052613A1 (en) 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Publications (1)

Publication Number Publication Date
SG11201401207XA true SG11201401207XA (en) 2014-05-29

Family

ID=48044139

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401207XA SG11201401207XA (en) 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Country Status (13)

Country Link
US (2) US20140249154A1 (enExample)
EP (1) EP2763674A4 (enExample)
JP (2) JP6240078B2 (enExample)
KR (1) KR20140071472A (enExample)
CN (1) CN103957908A (enExample)
AU (1) AU2012318670B2 (enExample)
BR (1) BR112014007963A2 (enExample)
CA (1) CA2850779A1 (enExample)
HK (1) HK1200361A1 (enExample)
IL (1) IL231923A0 (enExample)
PH (1) PH12014500724A1 (enExample)
SG (1) SG11201401207XA (enExample)
WO (1) WO2013052613A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9582896B2 (en) * 2011-09-02 2017-02-28 Qualcomm Incorporated Line tracking with automatic model initialization by graph matching and cycle detection
MX364295B (es) * 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
US20160031874A1 (en) * 2013-03-13 2016-02-04 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
PL2994465T3 (pl) 2013-05-10 2019-01-31 Karus Therapeutics Limited Nowe inhibitory deacetylazy histonowej
WO2016046759A2 (en) 2014-09-22 2016-03-31 Fratagene Therapeutics Ltd. Compositions and methods for treating friedreich's ataxia
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
HK1252120A1 (zh) * 2015-04-29 2019-05-17 Takeda Pharmaceutical Company Limited 抗病毒和抗炎疗法的治疗组合
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
EP3481810A4 (en) * 2016-07-11 2019-05-29 Baruch S. Blumberg Institute SUBSTITUTED AMINOTHIAZOLE
IL271491B2 (en) * 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
CN116547282A (zh) * 2020-10-23 2023-08-04 新基公司 杂环化合物及其用于治疗蠕虫感染和疾病的用途
WO2025017207A1 (en) 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
WO2025151517A1 (en) * 2024-01-08 2025-07-17 Wavebreak Therapeutics Limited Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
NZ530950A (en) * 2001-08-13 2006-03-31 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
AU2005230878A1 (en) * 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
EP1740155A1 (en) * 2004-04-13 2007-01-10 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
WO2006122011A2 (en) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JP2009529059A (ja) * 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ,インコーポレーテッド 抗c型肝炎ウイルス活性を有する置換アミノチアゾール誘導体
US9034574B2 (en) * 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators

Also Published As

Publication number Publication date
EP2763674A1 (en) 2014-08-13
AU2012318670B2 (en) 2017-09-07
JP6240078B2 (ja) 2017-11-29
CN103957908A (zh) 2014-07-30
JP2014528450A (ja) 2014-10-27
WO2013052613A1 (en) 2013-04-11
AU2012318670A1 (en) 2014-05-22
PH12014500724A1 (en) 2014-05-19
US20140249154A1 (en) 2014-09-04
CA2850779A1 (en) 2013-04-11
IL231923A0 (en) 2014-05-28
EP2763674A4 (en) 2015-04-29
KR20140071472A (ko) 2014-06-11
HK1200361A1 (en) 2015-08-07
BR112014007963A2 (pt) 2013-04-11
US10087173B2 (en) 2018-10-02
US20170066758A1 (en) 2017-03-09
JP2017149753A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
SG11201401207XA (en) Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
IL269662A (en) Hepatitis C virus inhibitors
HUS1700002I1 (hu) Hepatitis C vírus replikációjának inhibitorai
ZA201307914B (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
PL2628481T3 (pl) Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
IL224369B (en) Combinations of inhibitors for hepatitis c virus
ZA201303752B (en) Inhibitors of hepatitis c virus
ZA201306720B (en) Hepatitis c virus inhibitors
IL229270B (en) Hepatitis c virus inhibitors
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
ZA201309356B (en) Hepatitis c virus inhibitors
ZA201308011B (en) Processes for preparing inhibitors of the hepatitis c virus
IL232889A0 (en) Compounds and methods for treating hepatitis c virus